Leron actually binds to multiple cell types that possess CCR5! It's primary MOA is the prevention of CCL5 binding so that the cells responsible for causing the hyperinflammatory response never traffic their way into the tissue that's experiencing damage!
Also, it rather dramatically lowers IL-6 and CRP, both markers for inflammation as you know.
It also increases CD8+ T cell counts as well as reduces viral load to 0 byb day 14!
Not trying to argue or start a fight. Just wanted to share what's been learned!
Please direct me to the science that shows that Leronlimab is downstream from GM-CSF. That is not how I understand things.
CCR5 recieves the signals that send the cytokines to battle. Lenzi inhibits the production of the cytokines.
It would seem to me that both work. Perhaps they will be used together. I'm not going to argue with you about which is better, because I dont believe you have a complete understanding of Leronlimab.
News 
Market Data 
Discover 
